Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

PHASE1RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

September 4, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2025

Conditions
Advanced or Metastatic Solid TumorKRAS G12C Mutation
Interventions
DRUG

BEBT-607Tablets

"PhaseⅠa:100mg,200mg,300mg,400mg,600mg or 800mg/day,50mg,100mg,150mg,200mg,300mg or 400mg each time, once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days,28 days is as a treatment cycle.~PhaseⅠb:300mg,400mg or 600mg/day, 150mg,200mg or 300mg each time,twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days,28 days is as a treatment cycle."

Trial Locations (1)

410008

RECRUITING

Xiangya Hospital of Central South University, Changsha

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Xiangya Hospital of Central South University

OTHER

lead

BeBetter Med Inc

INDUSTRY